Jonathan Frantz

Jonathan M. Frantz is an American ophthalmologist known for his contributions to laser vision correction and cataract surgery. His research and clinical work have been part of efforts to develop ophthalmologic techniques and technologies. His involvement began with early studies on primates, which contributed to the research and development of laser vision correction in humans. Frantz served as an assistant surgeon in one of the first laser vision correction procedures conducted in the United States and has been a principal investigator in studies, including research that led to FDA approval of Excimer laser technology.
Early research and preclinical studies
Frantz participated in early research on photorefractive keratectomy (PRK), focusing on the procedure's safety and efficacy. He co-authored a study that evaluated the application of PRK in green monkeys to correct myopia.
The study found that PRK was effective in correcting myopia in green monkeys, producing stable changes in vision and promoting healthy corneal healing. The corneas healed successfully, exhibiting healthy tissue regeneration without recurring issues. After an initial period of mild haze, the corneas cleared by 17 weeks and remained clear throughout the year-long follow-up. The study also demonstrated that PRK led to consistent, stable changes in corneal shape by 17 weeks, ensuring predictable refractive outcomes. Additionally, the procedure confirmed that excimer laser technology could safely modify the cornea’s shape to improve vision. Researchers noted that mechanically removing the cornea’s outer layer, rather than using a laser for this step, appeared to be a more effective method for ensuring healing. These findings contributed to further research and clinical trials on PRK as a technique for correcting vision problems.
Role in FDA Trials
Frantz has served as a principal investigator in clinical trials that contributed to FDA approvals of ophthalmic treatments. He was an investigator in Phase III clinical trials for bimatoprost (Lumigan), a medication for glaucoma. The results, which demonstrated the drug's effectiveness over timolol, were published in peer-reviewed journals such as *Ophthalmology*. His participation in these trials reflects his involvement in national-level ophthalmic research.
Clinical Trials Leadership
Beyond industry-led trials, Frantz has been involved in NIH-sponsored research, including randomized clinical studies on glaucoma treatments published in Archives of Ophthalmology. He has presented research findings at the Association for Research in Vision and Ophthalmology (ARVO), with published abstracts in Investigative Ophthalmology & Visual Science since 1988.
Media Coverage
Frantz has been featured in various media reports regarding advancements in ophthalmic surgery. In 2019, WINK News (CBS affiliate) reported on his distinction as the first surgeon in Southwest Florida to implant the newly FDA-approved PanOptix trifocal intraocular lens for cataract patients. The Naples Daily News covered his introduction of the VERION image-guided surgery system, an advanced cataract surgery technology. His work has also been covered in industry publications such as *Ophthalmology Management* and *EyeWorld*.

Main Menu

See Also

Main Menu